BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...

In August, the U.S. Food and Drug Administration approved the new COVID-19 booster shots, but with certain restrictions.

Amendment includes finalized cash amount and updated CVR terms for tender offer- LAVA announces new date for extraordinary general meeting of ...

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...

The global Controlled-Release Drug Delivery Technology Market is poised for remarkable growth, estimated at USD 66.9 billion ...

Pfizer Inc. (NYSE: PFE, "Pfizer") will present data across its infectious disease portfolio at the upcoming IDWeek 2025 ...

J&J reports today, just two weeks after Pfizer secured certainty on tariffs and drug pricing. Analysts expect to hear about ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell ...

While the near-term forecast is revised up modestly, global growth remains subdued, as the newly introduced policies slowly come into focus The global economy is adjusting to a landscape reshaped by ...

Pfizer Inc. experiences a mixed bag in the options market as its shares dip slightly. Currently, the stock is trading down 16 ...